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Highlights 20 
1. Equine Gastric Ulcer Syndrome (EGUS) is the most common disease of the equine 21 
stomach with a high prevalence. 22 
2. Nutraceutical compounds have been shown to have a positive effect on preventing or 23 
healing naturally occurring gastric ulcers. 24 
3. pHyloGASTRO® is a herbal feed composed of medical herbs that act on restoring the 25 
acid-base balance. 26 
4. pHyloGASTRO® seems to be an effective feed additive for the improvement of gastric 27 
lesions.  28 
5. We believe that the 6-week treatment period, recommended by the manufacture, is too 29 
short, since often gastric mucosal lesions did not completely heal in our treated group.  30 
31 
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Abstract 32 
Equine Gastric Ulcer Syndrome (EGUS) is the most common disease of the equine 33 
stomach with high prevalence of both squamous and glandular disease reported in various 34 
populations. 35 
The aim of this study was to evaluate the effectiveness of a phytotherapic compound 36 
(pHhyloGASTRO®) in the therapy of EGUS. 37 
Materials and methods. The study was performed as a randomised double-blinded single 38 
centre study. The study population was composed of 19 equids which were submitted to 39 
gastroscopy before and after a six-week treatment with feed additive (10/19) 40 
(pHyloGASTRO®, 4Union B.I.O. srl, Italy) or a placebo (9/19). Severity grade was 41 
evaluated on a scale from 0-4. The variables of interest were gastric lesion score and 42 
improvement grade. Changes and comparisons of variables were performed by 43 
contingency table analyses. P level of significance was set at 0.05 in all analyses.  44 
Results. In terms of gastric lesion scores, the treated group improved significantly 45 
compared to the placebo group.  46 
Discussion and conclusions. pHyloGASTRO® seems to be effective in the treatment of 47 
EGUS. Further studies are needed to verify whether prolonged administration of 48 
pHyloGASTRO® could be more effective in completely healing gastric lesions.  49 
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1. Introduction 54 
Gastric ulceration is the most common disease of the equine stomach with a high 55 
prevalence of both squamous and glandular disease reported in various populations [1-3]. 56 
The term Equine Gastric Ulcer Syndrome (EGUS) was first adopted by the EGUS Council 57 
in 1999 and includes a complex of pathological conditions characterized by the presence 58 
of ulcers in the terminal portion of the oesophagus, in the proximal (squamous) and distal 59 
(glandular) parts of the stomach, and in the proximal part of the duodenum of equids [4]. 60 
Recently various authors [5-7] and the European College of Equine Internal Medicine 61 
(ECEIM) Consensus Statement [8] have provided a new nomenclature of EGUS and 62 
proposed updated guidelines regarding pathophysiology, diagnosis, and treatment [5,8].  63 
Many drugs have been investigated and are available for the treatment and management 64 
of EGUS [8-11]. The proton pump inhibitor omeprazole has been found to be very efficient 65 
in both treating and preventing gastric ulcers in horses [8]. Other drugs such as histamine2 66 
antagonists or gastric mucosal protectors have shown less efficacy than omeprazole in the 67 
treatment of EGUS [8,11,12].  68 
Along with pharmacological therapies, nutraceutical compounds appear to have a positive 69 
effect on preventing or healing naturally occurring gastric ulcers [13-20]. Thus, interest in 70 
more natural products has been growing. The purpose of this study was to evaluate the 71 
effect of the feed additive pHyloGASTRO® (Union B.I.O. srl, Italy) on the treatment of 72 
spontaneously occurring gastric ulcers of the squamous mucosa in a population of equids.  73 
 74 
2. Methods 75 
2.1 Materials 76 
The study population was composed of 19 equids (ten Standardbred trotting horses and 77 
nine Amiata donkeys). The equids were equal regarding distribution of gender and breed. 78 
None of the animals showed clinical signs of EGUS, were athletes and were used for 79 
reproduction. Inclusion criteria: 1) all the equids were affected by gastric ulcers at 80 
gastroscopy; no changes in the feeding and environment during the study period were 81 
made. 82 
2.2 Study design 83 
The study was performed as a randomised double-blinded single centre study and the 84 
protocol was approved by the Ethical Committee of the University of Pisa [no. 9069/2014]. 85 
Group allocation and blinding: once enrolled into the study, horses were randomly 86 
allocated to a dose group by pulling their names out of a hat. One investigator (F.B.) was 87 
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responsible for randomisation while another investigator (S.B.) remained blinded to the 88 
group allocation until scoring was completed and recorded.  89 
Ulcers were diagnosed by gastroscopy performed under sedation after 12 hours of fasting 90 
and 4 hours of water deprivation as reported in the literature [21]. Severity grade was 91 
evaluated on a scale from 0-4 as proposed by others [4]. Gastroscopy was always 92 
performed by the same operator (S.B.), as indicated by others [22]. For the examination, a 93 
300 cm scope (Karl Storz, Germany) and a portable processor (Gastropack, Karl Storz, 94 
Germany) were used. The images were stored on a DVD recorder. The stomach was 95 
insufflated with air through an air-flow system attached to the biopsy channel of the scope 96 
until the internal stomach folds appeared flattened. Feed material adhering to the non-97 
glandular mucosa was flushed away with sterile water in order to visualize the entire non-98 
glandular portion of the stomach, including the greater curvature, the lesser curvature, and 99 
the dorsal fundus. The number and degree of ulcers were recorded in accordance with the 100 
Equine Gastric Ulcer Council (EGUC) recommendations [4].  101 
Equids were divided in two groups: the “placebo group” was composed of 9/19 animals 102 
(median age 10 years); the “treated group” was composed of 10/19 animals (median age 8 103 
years). The two treatment groups were clinically equal regarding distribution of gender and 104 
breed. The “treated group” was treated with pHyloGASTRO® (Union B.I.O. srl, Italy) at a 105 
dose of 60 ml per equid BID PO for 6 weeks, while the “placebo group” was treated BID 106 
with a similar-looking same-volume placebo for 6 weeks. Both pHyloGASTRO® and 107 
placebo were administered using a feeding device. The administration was always 108 
performed by the same operator (C.G.). pHyloGASTRO® is composed of medical herbs 109 
(Althaea officinalis, Aloe barbadensis, Hoedeum vulgar, Malva sylvestris, Glycyrrhiza 110 
glabra, Echinacea angustifolia, calendula officinalis, Clay ventilated) powered by Matrix 111 
UB® (the aqueous extract of Olea europaea, a phyto-active enhancer). The medical herbs 112 
previously reported showed antinflammatory, cytoprotective, antioxidant, mucus healing, 113 
and acid-base balance restoring activities (table 1) [23-38]. A clinical examination was 114 
carried out daily for each animal to monitor gastro-intestinal side effect. All the equids were 115 
submitted to a gastroscopy after the 6-week treatment.  116 
2.3 Statistical analysis 117 
The variables of interest were gastric lesion score and improvement grade. Changes and 118 
comparisons on variables were performed by contingency table analyses. Significance 119 
was set at 0.05 in all analyses. All the analyses were performed using a GraphPad Prism 120 
6.0 (USA).  121 
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3. Results 123 
All the equids in the study were affected by gastric ulcers in the non-glandular mucosa 124 
(Equine Squamous Gastric Disease, ESGD) [5,8]. No health problems or side effects 125 
(diarrhoea, stipsis, disorexia or anorexia, colic) related to treatment with pHyloGASTRO® 126 
were observed during the all study period. The feed additive was readily accepted by all 127 
the pHyloGASTRO®-treated horses in the same manner as the placebo. 128 
Before treatment, the “treated group” equids showed 2/10 grade 1, 6/10 grade 2, 1/10 129 
grade 3, while no equids showed grade 4; the “placebo group” equids showed 3/9 grade 1, 130 
3/9 grade 2, 3/9 grade 3, while no equids showed grade 4. The pre-treatment distribution 131 
of gastric lesion scores was not significantly different between the two groups. 132 
 After 6 weeks of treatment, the “treated group” showed 2/10 equids with grade 0, 7/10 133 
with grade 1, 1/10 with grade 3, while no animals showed grades 2 and 4; the “placebo 134 
group” showed 2/9 with grade 0, 2/9 with grade 1, 3/9 with grade 2, and 2/9 with grade 3, 135 
while no animals showed grade 4. Outcomes for both “placebo” and “treated” groups are 136 
reported in table 2. 137 
 The “treated group” improved significantly compared to the “placebo group” (p=0.04). 138 
Concerning the improvement score of the gastric lesions, equids treated with 139 
pHyloGASTRO® showed a significantly (p=0.0001) higher improvement than equids 140 
treated with the placebo (Table 3). 141 
No differences were found between the two groups considering complete healing of gastric 142 
lesions vs improvement. 143 
 144 
4. Discussion 145 
EGUS is a complex disease, which for nearly 30 years has been recognized as a highly 146 
prevalent condition both in training and at rest horses [5,8,11]. A new nomenclature of 147 
EGUS along with updated guidelines regarding pathophysiology, diagnosis, and treatment 148 
have recently been proposed [5-8]. In particular, the European College of Equine Internal 149 
Medicine (ECEIM) committee recognizes that the terminology for EGUS needed 150 
clarification and proposes the nomenclature of Equine Squamous Gastric Disease (ESGD) 151 
amd Equine Glandular Gastric Disease (EGGD) [15]. 152 
The pharmacology products most commonly used for the treatment of gastric ulcers in 153 
horses focus on blocking gastric acid secretion and increasing stomach pH, which creates 154 
a permissive environment for physiological ulcer healing [8,10-11]. However, the research 155 
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for methods to treat or prevent gastric ulcers effectively without requiring the continued 156 
administration of costly pharmaceutical agents together with issues regarding withdrawal 157 
times or side effects is a new trend not only in human medicine, but also in veterinary 158 
medicine.  159 
In order to meet this growing need for more natural products, this study aimed to evaluate 160 
the effectiveness of pHyloGASTRO® in the treatment of EGUS in adult equids. Our results 161 
showed an easy administration and ingestion of pHyloGASTRO® by the treated horses, 162 
with no health problems or side effects related to the treatment. A total of 44.4% of the 163 
“placebo” horses and 80% of the “treated” horses showed an improvement or a complete 164 
healing of the ulcers.  165 
The improvement in the degree of ulceration score in the “placebo” group was similar 166 
compared to previous studies [17]. An improvement in placebo-treated patients has been 167 
reported in humans [39-41] and some studies have been published in veterinary medicine 168 
[42-43]. 169 
Also the improvement in the degree of ulcerations in the “treated” group is in line with a 170 
previous study [17], which investigated the effect of a nutraceutical compound and found 171 
an improvement of 77.8% of the horses treated.  172 
Comparing the two groups, statistical calculations revealed a significant reduction in 173 
gastric mucosal lesions in the “treated” horses compared to the “placebo” group after six 174 
weeks of administration of the nutraceutical feed. This is in line with findings reported in 175 
previous papers where different nutraceutical compounds were tested [14-15,17,19-20].  176 
Concerning the gastric lesion scores, equids treated with pHyloGASTRO® improved more 177 
significantly (p=0.0001) than equids treated with the placebo. Our results are in line 178 
findings reported in the literature [17,19-20]. 179 
 180 
5. Conclusions 181 
pHyloGASTRO® seems to be an effective feed additive for the improvement of gastric 182 
lesions. However, the treatment period of six weeks, recommended by the manufacture, 183 
seems too short, since the gastric mucosal lesions had often not completely healed in the 184 
treated group. Thus, further studies are needed to verify whether a prolonged 185 
administration of pHyloGASTRO® could be more effective in obtaining a complete healing 186 
of gastric lesions. A limitation of the study could be the lack of a group treated only with the 187 
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Matrice UB® solution. The addition of this group could lead to understanding whether the 188 
improvement to EGUS lesions was due to medical herbs, to Matrice UB® or both. 189 
190 
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Medical herbs Mechanism of action Literature 
Althaea officinalis Antinflammatory, cytoprotective [23,24] 
Aloe barbadensis Antinflammatory, cytoprotective, mucus healing [23] 
Hordeum vulgare Cytoprotective, mucus healing, acid-base restoring [25] 
Malva sylvestris Anti ulcerogenic activity [26-28] 
Glycyrrhiza glabra Gastric healing [29-31] 
Echinacea angustifolia Oxidant-antioxidant balance [32] 
Calendula officinalis Antiulcer, antinflammatory effect [33] 
Clay ventilated Ulcer healing [34] 
Olea europea Gastroprotective agent, antioxidant activity [35-38] 
Table 1 – Mechanism of action of medical herbs that are compounds of 310 
pHyloGASTRO® (Union B.I.O. srl, Italy). 311 
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 320 
 321 
 322 
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 324 
Table 2 – Pre and post treatment lesion score outcome in “placebo” and “treated” groups. 325 
  326 
PLACEBO GROUP 
Pre-treatment lesion score Post-treatment lesion score 
3 3 
1 0 
2 2 
3 3 
1 0 
1 1 
2 1 
3 2 
2 2 
 
TREATED GROUP 
Pre-treatment lesion score Post-treatment lesion score 
3 3 
1 1 
3 1 
2 1 
1 0 
2 0 
2 1 
2 1 
2 1 
2 1 
 15 
 327 
  Improved No change P  
  -3 -2 -1 0  
Start vs 6 
weeks 
Control 
group  
0 0 4/9 5/9 0.0001 
Start vs 6 
weeks 
Treated 
group  
0 2/10 6/10 0/10 
Table 3 – Change in gastric lesion scores before and after 6-week period between 328 
“control” and “treated” groups. 329 
 330 
